ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Ekihiro Seki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9472-6085; OpenAlex author ID A5039550467; NIH RePORTER profile ID 9556538. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 2
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 grant · 2025: none · 2026: 1 grant

Papers 1

Exosome Migration Inhibitory Factor as a Marker and Therapeutic Target for Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2016.02.051 ↗

Grants 2

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shelly Chi-Loo Lu · 1 shared grant, 2024 · strength 0.72
- Grant Project 2 - Fatty Liver Predisposes to Metastasis: Role of Hepatic Stellate Cells P01CA233452 ↗
Neil A. Bhowmick · 1 shared grant, 2024 · strength 0.72
- Grant Project 2 - Fatty Liver Predisposes to Metastasis: Role of Hepatic Stellate Cells P01CA233452 ↗
Stephen Jacob Pandol · 1 shared paper, 2016 · strength 0.08
- Paper Exosome Migration Inhibitory Factor as a Marker and Therapeutic Target for Pancreatic Cancer. DOI 10.1053/j.gastro.2016.02.051 ↗
Hiroshi Matsushita · 1 shared paper, 2016 · strength 0.08
- Paper Exosome Migration Inhibitory Factor as a Marker and Therapeutic Target for Pancreatic Cancer. DOI 10.1053/j.gastro.2016.02.051 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.